Published in Cancer Weekly, February 15th, 2005
The study will enroll approximately 60 patients into a 2-week in-house dosing and monitoring protocol. The study is being conducted in Berlin, Germany.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.